KPC Pharmaceuticals, Inc. (600422.SH): Approval granted for clinical trial of Gastrodin injection.

KPC Pharmaceuticals, Inc. (600422.SH) announced that the company has recently received the approved Clinical Trial Approval Notification for Tianmasu Injection issued by the National Medical Products Administration according to the classification of new drugs for chemical drugs as Class 2.4. The notification allows for the new drug to conduct relevant clinical trials. The indication for the new drug is to prevent postoperative delirium after cardiac surgery.